Insights on DPP4 inhibitors (DPP4i) and T2D management.

 

TRAJENTA® significant and sustained efficacy.

Linagliptin benefits: proven efficacy, ease of use: one dose, regardless of renal function

Prof Per-Henrik Groop

Nephrology and Folkhälsan Institute of Genetics, Folkhälsan Research Center University Central Hospital, Helsinki, Finland

Linagliptin: similar HbA1c reduction with 5mg dose in T2D patients whatever their renal function

Prof Melanie Davies

Diabetes Research Centre / Department of Health Sciences University of Leicester, United Kingdom

Renal excretion, kidney disease and DPP4i dosing

Linagliptin: no dose reduction and no need to monitor the dose based on renal function

Prof Mark Cooper

Department of diabetes Central Clinical School at Monash University, Australia

Many of T2D patients have chronic kidney disease and that can deteriorate over time

Prof Melanie Davies

Diabetes Research Centre / Department of Health Sciences University of Leicester, United Kingdom

TRAJENTA®: Favourable safety and tolerability profile for a broad range of patients.

Not having to dose adjust can simplify therapy for complex T2D patients

Prof Mike Cummings

Academic Department of Diabetes and Endocrinology Portsmouth NHS Trust Queen Alexandra Hospital Portsmouth Hampshire, United Kingdom

TRAJENTA® has demonstrated high efficacy on a broad range of T2D populations regardless of renal function

Prof Mike Cummings

Academic Department of Diabetes and Endocrinology Portsmouth NHS Trust Queen Alexandra Hospital Portsmouth Hampshire, United Kingdom

Linagliptin is suitable for a broad range of T2D patients


Prof Per-Henrik Groop

Nephrology and Folkhälsan Institute of Genetics, Folkhälsan Research Center University Central Hospital, Helsinki, Finland

JENTADUETO®: Significant HbA1c reductions for high-baseline T2D patients.

Linagliptin has demonstrated high efficacy in newly diagnosed patients with high baseline HbA1c

Prof Stefano Del Prato

Department of Endocrinology and Metabolism Section of Metabolic Disease and Diabetes University of Pisa, Italy

SPC metformin with linagliptin: the only DPP4i that does not require dose reduction when renal function declines

Prof Per-Henrik Groop

Nephrology and Folkhälsan Institute of Genetics, Folkhälsan Research Center University Central Hospital, Helsinki, Finland

How did you like this page?

Average: 4.3 (7 votes)